That's my point, the positive clinical trial update will need to occur after the consolidation and whether the much lower O/S makes a different. Over 2B shares got traded on the first clinical trial update for VAXINIA after the pps dropped to as low as 4c, I suspect the interest for OASIS will be even more considering the potential solid cancer market and the market has also ignored the development of VAXINIA and Azer-Cel.
IMU Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)